New Amsterdam Pharma
Dr. Michael Davidson joined NewAmsterdam Pharma as CEO and Executive Board member as of August 2020. Before Michael was founder and Chief Medical Officer of Corvidia Therapeutics which sold to Novo Nordisk in July 2020. Michael is a leading expert in the field of Lipidology and was named in The Best Doctors in America for the past 10 years.
Michael was the co-founding Chief Medical Officer of Omthera Pharmaceuticals in 2008, which was later acquired by Astra Zeneca Pharmaceutical in 2013 for $443M. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996.
His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Michael is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Michael received his BA/MS from Northwestern University and MD from The Ohio State University School of Medicine.
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.